Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: A multicenter, randomized prospective study. - Prospective study of omeprazole versus famotidine in patients with acute coronary syndromes

Division of Cardiology, Yokohama City University Medical Center0 个研究点目标入组 100 人开始时间: 2010年1月4日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) use of proton-pump inhibitors, H2-receptor antagonists, warfarin, ticlopidine, cilostazole, glycoprotein IIb/IIIa inhibitor, or fibrinolytics within 7 days before enrollment or duing study period. 2) serum hemoglobin level <10 g/dl or >18 g/dl 3) platelet count <100,000 /mm3 or >500,000 /mm3 4) hematologic or malignant disordor 5) past history of recent gastric or duodenal ulcer 6) major bleeding events within 7 days before enrollment 7) severe chronic renal failure (serum creatinine > 2mg/dl) 8) severe liver dysfunction (hepatic cirrhosis or portal hypertension) 9) acute coronary syndromes caused by stent thrombosis or in-stent restenosis 10) drug allergy of study drugs, aspirin or clopidogrel 11) participating in the other trial (phase 1-3) 12) women of pregnant, childbearing potential or lactation 13) patients who are not allowed to participate in the trial by judgement of the treating physician

发起方

Division of Cardiology, Yokohama City University Medical Center